Acute Isolated Mesenteric Artery Dissection: Four Year Experience From a French Intestinal Stroke Centre

Abstract

This study aimed to report outcomes of patients with symptomatic acute isolated mesenteric artery dissection (IMAD) treated within a French intestinal stroke centre (ISC). All patients with symptomatic IMAD referred to the ISC from January 2016 to January 2020 were included prospectively. Patients with aortic dissection and asymptomatic IMAD were not included. The standardised medical protocol included anticoagulation and antiplatelet therapy, gastrointestinal resting, and oral antibiotics. Operations were considered for acute mesenteric ischaemia (AMI). Among the 453 patients admitted to an ISC during the study period, 34 (median age, 53 years [41 - 67]; 82% men) with acute symptomatic IMAD were included. According to the classification of Yun etal., IMADs were reported as follows: type I (n= 7, 20%), type IIa (n= 6, 18%), type IIb (n= 15, 44%), and type III (i.e., complete superior mesenteric artery [SMA] occlusion; n= 6, 18%). Overall, nine (26%) patients had AMI (type I/II, n= 3; type III, n= 6). On initial computerised tomography angiogram, nine (26%) patients had an associated visceral arterial dissection or pseudoaneurysm. All patients with types I/II (n= 28, 82%) followed a favourable clinical course with conservative therapy, with no need for any operation. All patients with type III (n= 6, 18%) underwent urgent laparotomy with SMA revascularisation (open, n= 4; stenting, n= 1) and or bowel resection (early, n= 3; late, n= 1). Rates of intestinal resection and short bowel syndrome were 12% and 8.8%, respectively. After a median follow up of 26 months [18 - 42], recurrence of symptoms occurred in four (12%) patients and aneurysmal change in 14 (41%), with no re-intervention. Although IMAD was associated with a high frequency of AMI, a standardised protocol produced a low rate of intestinal resection. Conservative therapy seems appropriate in types I/II patients, whereas urgent SMA revascularisation should aim to avoid intestinal resection or death in type III patients.